Member Posts > Cardiol Therapeutics' CRD-38: A Novel Therapeutic Approach to Heart Failure by Cardiol Therapeutics
Cardiol Therapeutics is pioneering a new treatment strategy for heart failure (HF) with its innovative subcutaneous cannabidiol (CBD) formulation, CRD-38. The latest preclinical research, published in the Journal of the American College of Cardiology: Basic to Translational Science, highlights its potential in reducing the pathological remodeling, inflammation, and dysfunction associated with HF.
Understanding Heart Failure: A Growing Clinical Challenge
Heart failure is a complex and progressive condition that affects millions globally. Despite the availability of guideline-directed medical therapy (GDMT), a significant portion of patients continue to experience deteriorating cardiac function, particularly those with heart failure with preserved ejection fraction (HFpEF). CRD-38 aims to bridge this gap by targeting the inflammatory and structural abnormalities that drive disease progression.
How CRD-38 Works: A Multifaceted Mechanism
CRD-38 combines two key pharmacological actions:
1. Cannabidiol's Anti-Inflammatory Properties: The activation of CB2 receptors has been shown to suppress inflammation, a key contributor to cardiac damage in HF.
2. Vasodilatory Effects of Organic Nitrates: By relaxing vascular smooth muscles, these compounds enhance coronary blood flow, improving myocardial oxygen supply.
Preclinical Study Highlights
In HF models, CRD-38 led to:
• Reduced cardiac hypertrophy and fibrosis-mitigating adverse remodeling.
• Improved ventricular function-enhancing cardiac output and ejection fraction.
• Lowered markers of inflammation and apoptosis-preserving cellular health.
Implications for Clinical Practice
With HFpEF remaining a difficult-to-treat condition, CRD-38's unique mechanism offers a new therapeutic pathway. The subcutaneous delivery also addresses medication adherence challenges.
Next Steps in Development
Cardiol Therapeutics is preparing CRD-38 for clinical trials, with the goal of transforming HF management. If successful, it could represent a paradigm shift in cardiovascular medicine.

#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs